EBIT: Income before interest and taxes.
SELLAS Life Sciences Group, Inc. (SLS) had EBIT of $-7.08M for the most recently reported fiscal quarter, ending 2025-09-30.
| Income Statement Financials | |
-- |
|
$-6.79M |
|
-- |
|
-- |
|
$7.08M |
|
$-7.08M |
|
$0.29M |
|
$-6.79M |
|
$-6.79M |
|
$-6.79M |
|
$-6.79M |
|
$-6.79M |
|
$-6.79M |
|
|
EBIT |
$-7.08M |
$-7.08M |
|
108.40M |
|
108.40M |
|
$-0.06 |
|
$-0.06 |
|
| Balance Sheet Financials | |
$49.05M |
|
-- |
|
$2.50M |
|
$51.55M |
|
$5.92M |
|
-- |
|
-- |
|
$5.92M |
|
$45.63M |
|
$43.72M |
|
$45.63M |
|
125.08M |
|
| Cash Flow Statement Financials | |
$-23.47M |
|
-- |
|
$53.90M |
|
$13.99M |
|
$44.42M |
|
$30.43M |
|
$1.51M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
8.28 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-23.47M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-14.88% |
|
-15.53% |
|
-13.17% |
|
-14.88% |
|
$0.36 |
|
$-0.22 |
|
$-0.22 |
|